Ahmed Hamdy MD

Ahmed Hamdy MD is a declared insider at 3 companies (chief executive); the most frequent names are Vincerx Pharma, Inc., Pharmacyclics Inc and Curis Inc. The record holds 13 filings, for trades running from 30 October 2009 to 20 March 2026.

Both buying and selling appear: 6 purchases worth €222k, against 1 sale worth €89k. The net balance comes to €133k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 1 option exercise.

The median purchase comes to €31k. Of 5 purchases, 5 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 23 March 2026 came the latest disclosure, a transaction in Curis Inc. The last purchase on record was published on 10 August 2023, which is 1,170 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.